Nuclera logo

Nuclera

Bring rapid protein access to your benchtop with eProtein Discovery

114 employees · est. 2013 · Cambridge, United Kingdom

VS
SpliceBio logo

SpliceBio

Biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies.

39 employees · est. 2012 · Barcelona, Spain

SpliceBio is the older company (2013 vs 2012); Nuclera is the larger of the two.

Side-by-Side Comparison

Nuclera SpliceBio
Founded
2013 2012 older
Headquarters
Cambridge, United Kingdom Barcelona, Spain
Employees
114 larger 39
Industry
Biotechnology, Life Sciences, Pharmaceutical Biotechnology, Life Sciences, Pharmaceutical
Funding Stage
Series C Series A
Total Funding
$207.83M $51.70M
Funding Rounds
9 3
Services
eProtein Discovery System, Antibody Screening Services, Protein Design and Expression, Membrane Protein Production Not tracked yet
Target Customers
Biotechnologists, Pharmaceutical Researchers, Drug Discovery Scientists, Structural Biologists, Academic Research Institutions Not tracked yet
Taxonomy
Protein Science, Multiplex Protein Screening, Cell-free Expression Systems, Digital Microfluidics, Protein Characterization, Drug Discovery, Membrane Proteins, Biotech Innovation, Research Acceleration, Protein Optimization, Lab Automation, Protein Synthesis, Biotech Startup, Scientific Research Tools, Rapid Protein Prototyping Protein Splicing, Gene Therapies, Platform Technology, Intein, Protein Engineering, Research, Start-up, Investment, UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund, Asabys Partners
Website
nuclera.com splice.bio
Nuclera logo

About Nuclera

Nuclera, founded in 2013 by PhD students at the University of Cambridge, has positioned itself as a transformative player in the biotechnology, life sciences, and pharmaceutical industries. With its headquarters in the United Kingdom and a burgeoning presence in Boston, MA, the company employs over...

SpliceBio logo

About SpliceBio

SpliceBio is a biotechnology company that specializes in exploiting Protein Splicing to develop the next generation of gene therapies. The company's proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein...

We will tell you when either one moves

BounceWatch watches Nuclera and SpliceBio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Nuclera and SpliceBio — by email.

Frequently Asked Questions

Nuclera — Bring rapid protein access to your benchtop with eProtein Discovery. SpliceBio — Biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Nuclera has raised $207.83M while SpliceBio has raised $51.70M.
Nuclera and SpliceBio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Nuclera with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Nuclera on 15 Jun 2026, and SpliceBio on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy